Gubra at ObesityWeek 2026

Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website

Gubra brings 4 presentations to ObesityWeek 2026 in National Harbor. Its posters present rodent models for obesity drug research, including sarcopenic obesity and dexamethasone-induced muscle atrophy for studying healthy weight loss. Others compare CagriSema with cagrilintide and semaglutide in obese rats and show orforglipron activating appetite-suppressing brain regions in a human GLP-1 receptor model.

OrganizationObesityWeek 2026 Attendance
Gubra
Hørsholm, Denmark
Preclinical tools & services
Preclinical CRO and peptide drug-discovery company offering obesity and metabolic disease models and studies.
Poster
Sat Nov 14
7:30pm–8:30pm
Modeling Sarcopenic Obesity for Treatment of Healthy Weight Loss
Obesity pharmacotherapy and drug developmentMetabolism and integrative physiology
Poster
Sat Nov 14
7:30pm–8:30pm

Explore the full ObesityWeek 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in National Harbor. Leave your work email and we’ll be in touch.

Privacy

Download the full ObesityWeek 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Gubra

Tell us what you sell and we’ll find the people at Gubra most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction